Home > Journals > International Angiology > Past Issues > International Angiology 2015 August;34(4) > International Angiology 2015 August;34(4):398-406

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLES   

International Angiology 2015 August;34(4):398-406

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Flow-mediated dilation benefits of mesoglycan in peripheral artery disease

Gossetti B. 1, 2, Antignani P. L. 1, 2, Jabbour J. 1, 2, Martinelli O. 1, 2

1 Vascular Surgery and Emergency Vascular Surgery Division, Azienda Policlinico Umberto I, Rome, Italy; 2 Department of Vascular Surgery, Sapienza University, Rome, Italy


PDF


AIM: Mesoglycan, composed of natural glycosaminoglycans, is used for treatment in arterial and venous disease for its benefits on endothelial glicocalix. Little is known about mesoglycan impact on endothelial blood flow regulation. We sought to evaluate the effects of mesoglycan intermittently added to back-ground treatments on impairment of endothelial function in peripheral arterial disease (PAD) patients.
METHODS: We studied the effects of a 2+2 months oral treatment with 50 mg b.i.d. of mesoglycan, intervalled by 2 months without mesoglycan, in 540 PAD patients on four occasions (visit 1: baseline, visit 2: 2 months, visit 3: 4 months and visit 4: 6 months). At these time visits we assessed brachial artery endothelial-dependent flow-mediated dilation (FMD), together with femoral intima-medial thickness (IMT), and walking distance (WD).
RESULTS: There were significant changes in FMD (1.88%, CI 95%: 1.13, 2.63; P<0.001), IMT (-0.05 mm, CI 95%: -0.07,-0.02; P<0.001) and WD (38,9%, CI 95% 33.2, 44.8; P<0.001). The positive effects and benefit were maintained during the two-months interval without mesoglycan treatment. Significant changes in FMD were observed in a number of patient groups, stratified for risk factors (aging, sex, smoke, diabetes, dyslipidemia, hypertension).
CONCLUSION: Two months cycles with mesoglycan improved endothelial function in PAD patients, with a parallel reduction of atherosclerotic damage and amelioration of clinical condition.

top of page